State of New Jersey Common Pension Fund D Makes New Investment in Mirum Pharmaceuticals, Inc. $MIRM

State of New Jersey Common Pension Fund D acquired a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 30,800 shares of the company’s stock, valued at approximately $2,258,000.

Other large investors have also made changes to their positions in the company. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares during the period. CWM LLC boosted its holdings in Mirum Pharmaceuticals by 30.8% in the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the last quarter. Comerica Bank grew its position in Mirum Pharmaceuticals by 45.1% during the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares during the period. Jones Financial Companies Lllp raised its stake in shares of Mirum Pharmaceuticals by 34.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 957 shares of the company’s stock valued at $70,000 after buying an additional 243 shares during the last quarter. Finally, Osaic Holdings Inc. raised its stake in shares of Mirum Pharmaceuticals by 46.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after buying an additional 351 shares during the last quarter.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, CFO Eric Bjerkholt sold 1,053 shares of the stock in a transaction dated Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the completion of the sale, the chief financial officer directly owned 43,741 shares in the company, valued at $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Peter Radovich sold 2,631 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total transaction of $271,782.30. Following the completion of the transaction, the chief operating officer directly owned 20,655 shares in the company, valued at approximately $2,133,661.50. This represents a 11.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is owned by company insiders.

Mirum Pharmaceuticals Stock Down 0.3%

Shares of MIRM opened at $105.16 on Monday. The stock has a 50 day moving average price of $90.24 and a 200 day moving average price of $77.94. Mirum Pharmaceuticals, Inc. has a one year low of $36.88 and a one year high of $107.41. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The stock has a market capitalization of $5.40 billion, a price-to-earnings ratio of -122.28 and a beta of 0.49.

Analyst Ratings Changes

A number of brokerages have issued reports on MIRM. Morgan Stanley increased their price target on Mirum Pharmaceuticals from $95.00 to $123.00 and gave the stock an “overweight” rating in a research report on Friday, January 30th. Cantor Fitzgerald reissued an “overweight” rating and issued a $130.00 price target on shares of Mirum Pharmaceuticals in a research note on Monday, December 8th. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Evercore restated an “outperform” rating and set a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. Finally, Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the company an “outperform” rating in a report on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.17.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.